PURPOSE: The regimens of weekly irinotecan with platinum have been used for treatment of metastatic small-cell lung cancer (SCLC). We conducted a multi-institution phase II trial to evaluate a novel 21-day schedule of irinotecan and carboplatin in patients with relapsed or extensive SCLC. PATIENTS AND METHODS: Eighty patients were enrolled with the following characteristics: 39 male patients, 41 female patients; median age, 65 years; and Zubrod performance status, 0 to 1 in 85% and 2 in 15% of patients. Dosing schemas were based on the maximum-tolerated dose derived in a previous phase I study. Chemotherapy-naive patients with extensive SCLC were treated with irinotecan 200 mg/m(2) and carboplatin area under the curve (AUC) of 5 (arm A). Patients, who had previously been treated with chemotherapy and had relapsed disease received irinotecan 150 mg/m(2) and carboplatin AUC of 5 (arm B). In each study arm, the treatment was given every 21 days for up to six cycles. RESULTS: The most common grade 3 to 4 toxicities included neutropenia (54%), thrombocytopenia (22%), anemia (13%), diarrhea (22%), and nausea/emesis (11%) in both study arms. There were three treatment-related deaths owing to neutropenic sepsis. Among 72 assessable patients, response rates of 65% and 50% were observed, respectively, for arm A and arm B. The median survival for both study arms was identical at 10 months (95% CI, 6 to 14 months). A response rate of 65% was observed in the intracranial disease of 14 patients with known brain metastases. CONCLUSION: This 21-day regimen of irinotecan and carboplatin seems promising for the treatment of relapsed SCLC.
PURPOSE: The regimens of weekly irinotecan with platinum have been used for treatment of metastatic small-cell lung cancer (SCLC). We conducted a multi-institution phase II trial to evaluate a novel 21-day schedule of irinotecan and carboplatin in patients with relapsed or extensive SCLC. PATIENTS AND METHODS: Eighty patients were enrolled with the following characteristics: 39 male patients, 41 female patients; median age, 65 years; and Zubrod performance status, 0 to 1 in 85% and 2 in 15% of patients. Dosing schemas were based on the maximum-tolerated dose derived in a previous phase I study. Chemotherapy-naive patients with extensive SCLC were treated with irinotecan 200 mg/m(2) and carboplatin area under the curve (AUC) of 5 (arm A). Patients, who had previously been treated with chemotherapy and had relapsed disease received irinotecan 150 mg/m(2) and carboplatin AUC of 5 (arm B). In each study arm, the treatment was given every 21 days for up to six cycles. RESULTS: The most common grade 3 to 4 toxicities included neutropenia (54%), thrombocytopenia (22%), anemia (13%), diarrhea (22%), and nausea/emesis (11%) in both study arms. There were three treatment-related deaths owing to neutropenic sepsis. Among 72 assessable patients, response rates of 65% and 50% were observed, respectively, for arm A and arm B. The median survival for both study arms was identical at 10 months (95% CI, 6 to 14 months). A response rate of 65% was observed in the intracranial disease of 14 patients with known brain metastases. CONCLUSION: This 21-day regimen of irinotecan and carboplatin seems promising for the treatment of relapsed SCLC.
Authors: Stein Sundstrøm; Roy M Bremnes; Stein Kaasa; Ulf Aasebø; Reidulv Hatlevoll; Ragnar Dahle; Nils Boye; Mari Wang; Tor Vigander; Jan Vilsvik; Eva Skovlund; Einar Hannisdal; Steinar Aamdal Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: K James; E Eisenhauer; M Christian; M Terenziani; D Vena; A Muldal; P Therasse Journal: J Natl Cancer Inst Date: 1999-03-17 Impact factor: 13.506
Authors: A Schmittel; L Fischer von Weikersthal; M Sebastian; P Martus; K Schulze; P Hortig; M Reeb; E Thiel; U Keilholz Journal: Ann Oncol Date: 2006-01-19 Impact factor: 32.976
Authors: Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544
Authors: D V Skarlos; E Samantas; P Kosmidis; G Fountzilas; M Angelidou; P Palamidas; N Mylonakis; A Provata; E Papadakis; G Klouvas Journal: Ann Oncol Date: 1994-09 Impact factor: 32.976
Authors: Carolyn A Wild; Stephen E Wang; David R Gandara; Primo N Lara; Frederick J Meyers; Michael Tanaka; Joan Houston; Jun Lauder; Derick H Lau Journal: Oncology (Williston Park) Date: 2003-07 Impact factor: 2.990
Authors: T Korkmaz; S Seber; U Kefeli; E Sari; M Canhoroz; B Oven; E Yildirim; N Yasar; D Aydin; O Balvan; N Sener; S Yuksel; A Mert; O Polat; F Yumuk; O Kanat; M Gumus; N S Turhal Journal: Clin Transl Oncol Date: 2012-11-10 Impact factor: 3.405
Authors: Young Saing Kim; Se Hoon Park; Sun Young Kyung; Sun Jin Sym; Sang Pyo Lee; Jeong Woong Park; Sung Hwan Jung; Jinny Park; Eun Kyung Cho; Jae Hoon Lee; Dong Bok Shin Journal: Med Oncol Date: 2010-03-03 Impact factor: 3.064
Authors: David A Reardon; Annick Desjardins; Katherine B Peters; James J Vredenburgh; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; April Coan; Stevie Threatt; Allan H Friedman; Henry S Friedman Journal: Cancer Date: 2011-05-16 Impact factor: 6.860